Karyopharm Therapeutics Inc.

NASDAQ:KPTI

0.62 (USD) • At close February 4, 2025
Bedrijfsnaam Karyopharm Therapeutics Inc.
Symbool KPTI
Munteenheid USD
Prijs 0.62
Beurswaarde 78,200,563
Dividendpercentage 0%
52-weken bereik 0.581 - 1.95
Industrie Biotechnology
Sector Healthcare
CEO Mr. Richard A. Paulson M.B.A.
Website https://www.karyopharm.com

An error occurred while fetching data.

Over Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.

Vergelijkbare Aandelen

Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc.

NAUT

1.74 USD

2seventy bio, Inc. logo

2seventy bio, Inc.

TSVT

2.72 USD

Immatics N.V. logo

Immatics N.V.

IMTX

5.42 USD

Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc.

ATRA

9.3 USD

Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc.

ARCT

16.05 USD

Cara Therapeutics, Inc. logo

Cara Therapeutics, Inc.

CARA

4.91 USD

Immunovant, Inc. logo

Immunovant, Inc.

IMVT

20.91 USD

908 Devices Inc. logo

908 Devices Inc.

MASS

2.37 USD

Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc.

VERA

38.07 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)